These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 21954275

  • 21. The use of rapid coverage monitoring in the national rubella vaccination campaign, Haiti 2007-2008.
    Lacapère F, Magloire R, Danovaro-Holliday MC, Flannery B, Chamoulliet H, Celestin EP.
    J Infect Dis; 2011 Sep 01; 204 Suppl 2():S698-705. PubMed ID: 21954269
    [Abstract] [Full Text] [Related]

  • 22. Guide to the management of rubella problems.
    Middleton PJ, Larke RP, Lessard P, Doran TA.
    Can Med Assoc J; 1977 Mar 05; 116(5):484-8. PubMed ID: 837313
    [Abstract] [Full Text] [Related]

  • 23. Rubella in pregnancy: intrauterine transmission and perinatal outcome during a Brazilian epidemic.
    Andrade JQ, Bunduki V, Curti SP, Figueiredo CA, de Oliveira MI, Zugaib M.
    J Clin Virol; 2006 Mar 05; 35(3):285-91. PubMed ID: 16310405
    [Abstract] [Full Text] [Related]

  • 24. Fetal risk associated with rubella vaccine: implications for vaccination of susceptible women.
    Preblud SR, Williams NM.
    Obstet Gynecol; 1985 Jul 05; 66(1):121-3. PubMed ID: 4011062
    [Abstract] [Full Text] [Related]

  • 25. Postinfection and postvaccination antirubella immunity.
    Kańtoch M, Imbs D.
    Acta Virol; 1986 Sep 05; 30(5):381-9. PubMed ID: 2878585
    [Abstract] [Full Text] [Related]

  • 26. Rubella vaccination during the preconception period or in pregnancy and perinatal and fetal outcomes.
    Ergenoğlu AM, Yeniel AO, Yildirim N, Kazandi M, Akercan F, Sağol S.
    Turk J Pediatr; 2012 Sep 05; 54(3):230-3. PubMed ID: 23094531
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Rubella and congenital rubella syndrome elimination activities: Colombia, 2005-2006.
    Urquijo L, Pastor D, Velandia MP, Vicari AS.
    J Infect Dis; 2011 Sep 01; 204 Suppl 2():S603-7. PubMed ID: 21954254
    [Abstract] [Full Text] [Related]

  • 30. Fetal risk associated with rubella vaccine.
    Preblud SR, Stetler HC, Frank JA, Greaves WL, Hinman AR, Herrmann KL.
    JAMA; 1981 Sep 25; 246(13):1413-7. PubMed ID: 7265443
    [Abstract] [Full Text] [Related]

  • 31. Last cases of rubella and congenital rubella syndrome in Spain, 1997-2016: The success of a vaccination program.
    Seppälä EM, López-Perea N, Torres de Mier MV, Echevarría JE, Fernández-García A, Masa-Calles J.
    Vaccine; 2019 Jan 03; 37(1):169-175. PubMed ID: 30454948
    [Abstract] [Full Text] [Related]

  • 32. Top end rural and remote Indigenous women: an Australian population group vulnerable to rubella.
    Hunt JM, Lumley J.
    Commun Dis Intell Q Rep; 2004 Jan 03; 28(4):499-503. PubMed ID: 15745399
    [Abstract] [Full Text] [Related]

  • 33. Fetal risk associated with rubella vaccine: an update.
    Bart SW, Stetler HC, Preblud SR, Williams NM, Orenstein WA, Bart KJ, Hinman AR, Herrmann KL.
    Rev Infect Dis; 1985 Jan 03; 7 Suppl 1():S95-102. PubMed ID: 4001743
    [Abstract] [Full Text] [Related]

  • 34. Optimum use of rubella immunization.
    Mayer TR.
    Am Fam Physician; 1981 Jan 03; 23(1):143-5. PubMed ID: 7457312
    [Abstract] [Full Text] [Related]

  • 35. Premarital rubella screening program: from identification to vaccination of susceptible women in the state of Hawaii.
    Serdula MK, Marks JS, Remington PL, Ibara CM, White MC.
    Public Health Rep; 1986 Jan 03; 101(3):329-33. PubMed ID: 3086927
    [Abstract] [Full Text] [Related]

  • 36. Rubella surveillance to June 1994: third joint report from the PHLS and the National Congenital Rubella Surveillance Programme.
    Miller E, Tookey P, Morgan-Capner P, Hesketh L, Brown D, Waight P, Vurdien J, Jones G, Peckham C.
    Commun Dis Rep CDR Rev; 1994 Nov 11; 4(12):R146-52. PubMed ID: 7529090
    [Abstract] [Full Text] [Related]

  • 37. Distinguishing between primary infection and reinfection with rubella vaccine virus by IgG avidity assay in pregnant women.
    Hamkar R, Jalilvand S, Abdolbaghi MH, Jelyani KN, Esteghamati A, Hagh-goo A, Mohktari-Azad T, Nategh R.
    East Mediterr Health J; 2009 Nov 11; 15(1):94-103. PubMed ID: 19469431
    [Abstract] [Full Text] [Related]

  • 38. A review of five years' experience with rubella vaccine in the United States.
    Modlin JF, Brandling-Bennett AD, Witte JJ, Campbell CC, Meyers JD.
    Pediatrics; 1975 Jan 11; 55(1):20-9. PubMed ID: 1089240
    [Abstract] [Full Text] [Related]

  • 39. Screening and immunization of rubella-susceptible women. Experience in a large, prepaid medical group.
    Shlian DM.
    JAMA; 1978 Aug 18; 240(7):662-3. PubMed ID: 671687
    [Abstract] [Full Text] [Related]

  • 40. Seroprevalence of rubella antibodies in the State of São Paulo, Brazil, 8 years after the introduction of vaccine.
    Zanetta DM, Cabrera EM, Azevedo RS, Burattini MN, Massad E.
    Vaccine; 2003 Sep 08; 21(25-26):3795-800. PubMed ID: 12922113
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.